摘要
目的:分析高血压患者服药依从性、神经衰弱与睡眠质量的相关性。方法:选取2023年1月至2023年6月福清市海口镇中心卫生院内科高血压患者62例,分别采用匹兹堡睡眠质量指数(PSQI)、Morisky服药依从性评估量表(MMAS)、衰弱筛查量表(FRAIL)分别评估睡眠质量、服药依从性、神经衰弱情况,分析高血压患者Morisky评分、FRAIL评分与PSQI评分的相关性。结果:高血压患者Morisky评分、FRAIL评分与PSQI总分分别为(63.03±4.13)分、(2.13±1.22)分、(12.78±3.30)分。经Pearson分析,Morisky评分与PSQI各维度评分及总分呈负相关(P<0.05),FRAIL评分与PSQI各维度评分及总分呈正相关(P<0.05)。结论:高血压患者普遍服药依从性较低,且存在神经衰弱和睡眠问题,并且高血压患者的服药依从性、神经衰弱与睡眠质量密切相关,对此需提高患者的服药依从性,改善神经衰弱和睡眠质量。
Objective:To analyze the correlation between medication adherence,neurasthenia,and sleep quality in hypertensive patients.Methods:From January 2023 to June 2023,62 hypertensive patients from the Internal Medicine Department of Haikou Town Central Health Center in Fuqing City were selected.The Pittsburgh Sleep Quality Index(PSQI),Morisky Medication Adherence Scale(MMAS),and FRAIL Scale were used to evaluate sleep quality,medication adherence,and neurasthenia,respectively.The correlation between the Morisky score,FRAIL score,and PSQI score in hypertensive patients was analyzed.Results:The Morisky score,FRAIL score,and total PSQI score of hypertensive patients were(63.03±4.13),(2.13±1.22),and(12.78±3.30),respectively.According to Pearson analysis,the Morisky score was negatively correlated with all dimensions and the total score of the PSQI(P<0.05),while the FRAIL score was positively correlated with all dimensions and the total score of the PSQI(P<0.05).Conclusion:Hypertensive patients generally have low medication adherence and experience neurasthenia and sleep problems.The medication adherence,neurasthenia,and sleep quality of hypertensive patients are closely related.Therefore,it is necessary to improve patients′medication adherence and ameliorate neurasthenia and sleep quality.
作者
王国清
WANG Guoqing(Internal Medicine Department,Haikou Town Central Health Center,Fuqing Fuzhou,Fujian Province,Fuqing 350313,China)
出处
《世界睡眠医学杂志》
2024年第3期487-489,共3页
World Journal of Sleep Medicine
关键词
高血压
服药依从性
神经衰弱
睡眠质量
相关分析
疗效
问卷调查
Hypertension
Medication Adherence
Neurasthenia
Sleep Quality
Correlation Analysis
Therapeutic Effectiveness
Questionnaire Survey